The European Patent Office has granted Retarus a Europe-wide patent for the Patient Zero Detection® technology developed by the company. The innovative approach to analyzing and recognizing harmful emails is an integral component of the comprehensive E-Mail Security Services offered by the global information logistics provider. Patient Zero Detection® swiftly identifies recipients of new, previously unknown, malware. This enables administrators to react more quickly and, for instance with ransomware, avert substantial financial damage to the company before it is too late.
Extensive filtering performed by virus protection software is usually successful at blocking emails containing known malware reliably, before it has had the chance to find its way into the IT infrastructure. No virus filter, however, provides sufficient protection from targeted attacks using previously unknown or modified patterns of assault. When such malware first appears, it thus often sneaks into the company network unnoticed.
“That’s why we’re always seeking new ways to meet the increasing security requirements of our customers,” says Martin Hager, founder and CEO of Retarus. “The granting of this patent is further proof of the excellent work our development team is performing and the considerable innovative power at Retarus. At the same time, the patent is spurring us on – even after 25 years of experience in email security – to continue intensively developing our services ‘Made in Germany’.”
For further details please refer to our current press release.